Krystal Biotech (KRYS) Gross Profit (2023 - 2026)

Krystal Biotech (KRYS) has 4 years of Gross Profit data on file, last reported at $110.1 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 32.38% year-over-year to $110.1 million; the trailing twelve-month figure through Mar 2026 stood at $393.0 million (up 26.45% YoY), and the FY2025 full-year result was $366.1 million, up 35.36% from the prior year.
• Gross Profit rose to $110.1 million in Q1 2026, from $100.5 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $110.1 million in Q1 2026 to a low of $8.3 million in Q3 2023.
• A 4-year average of $72.2 million and a median of $83.2 million in 2025 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit jumped 825.92% in 2024 and gained 16.62% in 2025, its largest moves.
• Tracing KRYS's Gross Profit over 4 years: stood at $39.3 million in 2023, then jumped by 119.47% to $86.2 million in 2024, then advanced by 16.62% to $100.5 million in 2025, then gained by 9.52% to $110.1 million in 2026.
• Business Quant data shows KRYS's Gross Profit at $110.1 million in Q1 2026, $100.5 million in Q4 2025, and $93.5 million in Q3 2025.